SWATHI KALIKI

Dr. SWATHI KALIKI

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2016 in Eye
Verified
Journal Article
Closed access
SKSWATHI KALIKI
SWATHI KALIKI
CSC L Shields
C L Shields

1 January 2015 in Indian Journal Of Ophthalmology
Verified
Journal Article
Open access
SKSWATHI KALIKI
SWATHI KALIKI
CSCarolL Shields
CarolL Shields
JSJerryA Shields
JerryA Shields
Uveal melanoma is the most common primary malignant tumor of the eye in adults, predominantly found in Caucasians. Local tumor control of uveal melanoma is excellent, yet this malignancy is associated with relatively high mortality secondary to metastasis. Various clinical, histopathological, cytogenetic features and gene expression features help in estimating the prognosis of uveal melanoma. The clinical features associated with poor prognosis in patients with uveal melanoma include older age at presentation, male gender, larger tumor basal diameter and thickness, ciliary body location, diffuse tumor configuration, association with ocular/oculodermal melanocytosis, extraocular tumor extension, and advanced tumor staging by American Joint Committee on Cancer classification. Histopathological features suggestive of poor prognosis include epithelioid cell type, high mitotic activity, higher values of mean diameter of ten largest nucleoli, higher microvascular density, extravascular matrix patterns, tumor-infiltrating lymphocytes, tumor-infiltrating macrophages, higher expression of insulin-like growth factor-1 receptor, and higher expression of human leukocyte antigen Class I and II. Monosomy 3, 1p loss, 6q loss, and 8q and those classified as Class II by gene expression are predictive of poor prognosis of uveal melanoma. In this review, we discuss the prognostic factors of uveal melanoma. A database search was performed on PubMed, using the terms "uvea," "iris," "ciliary body," "choroid," "melanoma," "uveal melanoma" and "prognosis," "metastasis," "genetic testing," "gene expression profiling." Relevant English language articles were extracted, reviewed, and referenced appropriately.

22 May 2015 in Eye
Verified
Journal Article
Open access
PDF file
SKSWATHI KALIKI
SWATHI KALIKI
AAA Ayyar
A Ayyar
TDT V Dave
T V Dave
MAM J Ali
M J Ali
DMD K Mishra
D K Mishra
MNM N Naik
M N Naik
Purpose To study the clinical and histopathological features of eyelid sebaceous gland carcinoma (SGC) and to evaluate the prognosis in the Asian-Indian population. Methods This is a retrospective study of 191 patients with SGC. Results The mean age at presentation of eyelid SGC was 57 years (median, 56 years). The tumor epicenter was most commonly located in the upper eyelid (n=125, 65%). The mean tumor basal diameter was 15 mm (median, 10 mm). There was evidence of tumor extension into the orbit (n=30, 16%), paranasal sinuses (n=3, 2%), and brain (n=1, 1%). Wide excision biopsy (n=146, 78%) was the most common treatment modality. Tumor recurrence was noted in 42 (24%) patients over a mean follow-up period of 29 months (median, 20 months). On the basis of the Kaplan–Meier estimate, lymph node metastasis occurred in 18%, systemic metastasis was detected in 10%, and death occurred in 2% of patients at 10 years. On multivariate analysis, the factors predicting locoregional lymph node and systemic metastasis were medial canthal involvement (P=0.004; P=0.013), lateral canthal involvement (P=0.013; P=0.025), tumor basal diameter >10 mm (P=0.002; P=0.002), and perivascular invasion (P=0.043; P10 mm (P=0.001). Conclusion Advanced eyelid SGC is a tumor associated with poor prognosis. In this study, canthal involvement, larger tumor diameter, and perivascular invasion were poor prognostic factors.

1 June 2015 in Ophthalmology
Verified
Journal Article
Closed access
SKSWATHI KALIKI
SWATHI KALIKI
VSVisweswaran Srinivasan
Visweswaran Srinivasan
AGAdit Gupta
Adit Gupta
DMDilip K. Mishra
Dilip K. Mishra
MNMilind N. Naik
Milind N. Naik

1 February 2019 in Retina
Verified
Journal Article
Closed access
SKSWATHI KALIKI
SWATHI KALIKI
APAnamika Patel
Anamika Patel
SISadiya Iram
Sadiya Iram
GRGeorge Bsc Ramappa
George Bsc Ramappa
AMAshik Mohamed
Ashik Mohamed
VPVijay A. R. Palkonda
Vijay A. R. Palkonda
Purpose: To study the clinical presentation, treatment, and outcome of patients with retinoblastoma (RB) in India.Methods: Retrospective study of 1,457 patients with RB (2,074 eyes).Results: The mean age at presentation of RB was 29 months (median, 24 months; range, <1–370 months). There were 812 (56%) men and 645 (44%) women with unilateral presentation of RB in 57% (n = 834) and bilateral in 43% (n = 623). Familial RB was present in 4% (n = 55). The most common presenting complaints included leukocoria (n = 1,100; 75%), proptosis (n = 91; 6%), strabismus (n = 77; 5%), and red eye (n = 68; 5%). Most (n = 1,889; 91%) tumors were intraocular in location, and 185 (n = 185; 9%) had extraocular tumor extension at presentation. The most common modalities of primary treatment–included systemic chemotherapy (n = 1,171; 60%) and enucleation (n = 674; 35%). At a mean follow-up period of 44 months (median, 30 months; range, 3–234 months), 92% (n = 1,206) were alive, and 108 (8%) patients died because of RB. Based on Kaplan–Meier analysis, the survival at 1, 3, 5, and 10 years was 94%, 91%, 90%, and 89%, respectively.Conclusion: The most common presenting signs of RB in Asian Indian population are leukocoria and proptosis. With appropriate treatment, the survival rate is favorable at 92%.

1 August 2015 in Ophthalmology
Verified
Journal Article
Closed access
SKSaurabh Kamal
Saurabh Kamal
SKSWATHI KALIKI
SWATHI KALIKI
DMDilip K. Mishra
Dilip K. Mishra
JBJyoti Batra
Jyoti Batra
MNMilind N. Naik
Milind N. Naik